Advertisement

Nodal Malignant Lymphoma (With Comments on Extranodal Malignant Lymphoma and Metastatic Cancer)

  • Lakshmi VenkatramanEmail author
Chapter
  • 19 Downloads

Abstract

Nodal Malignant Lymphoma (with Comments on Extranodal Malignant Lymphoma and Metastatic Cancer): this chapter outlines the incidence, risk factors, clinical presentation, investigations, treatments and prognosis of cancer relating to lymph nodes. These features are correlated with the core data that are required to make corresponding histopathology reports of a consistently high quality, available in an appropriate timeframe, and clinically relevant to patient management and prognosis. Summary details of the common cancers given at this site include: gross description, histological types, tumour grade/differentiation, extent of local tumour spread, lymphovascular involvement, and the status of excision margins. Current WHO Classifications of Malignant Tumours and relevant staging are referenced. Notes are provided on other associated pathology, contemporary use of immunohistochemistry, updates on the role of evolving molecular tests, and the use of these ancillary techniques as biomarkers in diagnosis, and prediction of prognosis and treatment response.

Keywords

Lymphoma Ann Arbor staging 

References

  1. Alizadeh AA, Eisen MB, Davis RE. Distinct types of large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.CrossRefGoogle Scholar
  2. Attygalle AD, Cabeçadas J, Gaulard P, et al. Peripheral T-cell and NK-cell lymphomas and their mimics; taking a step forward—report on the lymphoma workshop of the XVIth meeting of the European Association for Haematopathology and the Society for Hematopathology. Histopathology. 2014;64:171–99.CrossRefGoogle Scholar
  3. Brown D, Gatter K, Natkunam Y. Bone marrow diagnosis: an illustrated guide. Hoboken, NJ: Wiley Blackwell; 2006.CrossRefGoogle Scholar
  4. Brunning RD, Arber DA. Bone marrow. Chapter 23. In: Rosai J, editor. Rosai and Ackerman’s surgical pathology. 10th ed. Amsterdam: Elsevier; 2011.Google Scholar
  5. Campo E, Chott A, Kinney MC, Leoncini L, Meijer CJLM, Papadimitriou CS, Piris MA, Stein H, Swerdlow SH. Update on extranodal lymphomas. Conclusions of the workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology. 2006;48:481–504.CrossRefGoogle Scholar
  6. Chan JKC. Tumours of the lymphoreticular system, including spleen and thymus. In: Fletcher CDM, editor. Diagnostic histopathology of tumours, vol. 2. 3rd ed. London: Harcourt; 2007. p. 1139–310.Google Scholar
  7. De Kerviler E, Guermazi A, Zagdanski AM, et al. Image-guided core-needle biopsy in patients with suspected or recurrent lymphoma. Cancer. 2000;89:647–52.CrossRefGoogle Scholar
  8. Dojcinov SD, Venkataraman G, Pittaluga S, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood. 2011;117:4726–35.CrossRefGoogle Scholar
  9. Du M-Q, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol. 2007;60:1350–7.CrossRefGoogle Scholar
  10. Rosai J. Lymph nodes, spleen. Chapter 22. In: Goldblum J, Lamps L, McKenney J, Myers J, editors. Rosai and Ackerman’s surgical pathology. 11th ed. Amsterdam: Elsevier; 2017.Google Scholar
  11. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2007;60:1365–72.CrossRefGoogle Scholar
  12. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.CrossRefGoogle Scholar
  13. Hart A, Lechowicz MJ. Breast implant-associated anaplastic large cell lymphoma: treatment experience in 53 patients. Blood. 2013;122:5089.CrossRefGoogle Scholar
  14. Intlekofer AM, Joffe E, Batlevi CL, et al. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J. 2018;8:60.CrossRefGoogle Scholar
  15. Kapatai G, Murray P. Contribution of the Epstein-Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol. 2007;60:1342–9.CrossRefGoogle Scholar
  16. Kocjan C. Cytological and molecular diagnosis of lymphoma. ACP best practice no 185. J Clin Pathol. 2005;58:561–7.CrossRefGoogle Scholar
  17. Leoncini L, Delsol G, Gascoyne RD, Harris NL, Pileri SA, Piris MA, Stein H. Aggressive B-cell lymphomas: a review based on the workshop of the XI meeting of the European Association for Haematopathology. Histopathology. 2005;46:241–55.CrossRefGoogle Scholar
  18. Maes B, De Wolf-Peeters C. Marginal zone cell lymphoma—an update on recent advances. Histopathology. 2002;40:117–26.CrossRefGoogle Scholar
  19. Matutes E. Adult T-cell leukaemia/lymphoma. J Clin Pathol. 2007;60:1373–7.CrossRefGoogle Scholar
  20. Műller-Hermelink HK, Zettl A, Pfeifer W, Ott G. Pathology of lymphoma progression. Histopathology. 2001;38:285–306.CrossRefGoogle Scholar
  21. O’Malley DP, George TI, Orazi A, editors. Benign and reactive conditions of lymph node and spleen. Washington DC: ARP Press; 2009.Google Scholar
  22. Oudejans JJ, van der Walk P. Diagnostic brief. Immunohistochemical classification of B cell neoplasms. J Clin Pathol. 2003;56:193.CrossRefGoogle Scholar
  23. Prakash S, Swerdlow SH. Nodal aggressive B-cell lymphomas: a diagnostic approach. J Clin Pathol. 2007;60:1076–85.CrossRefGoogle Scholar
  24. Sagaert X, De Wolf-Peeters C. Anaplastic large cell lymphoma. Curr Diagn Pathol. 2003;9:252–8.CrossRefGoogle Scholar
  25. Salaverria I, Martin-Guerrero I, Wagener R, et al. A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma. Blood. 2014;123:1187–98.CrossRefGoogle Scholar
  26. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–61.CrossRefGoogle Scholar
  27. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRefGoogle Scholar
  28. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haemopoietic and lymphoid tissues. 4th ed. Lyon: IARC Press; 2017.Google Scholar
  29. Tapia G, Lopez R, Munoz-Marmol AM, Mate JL, Sanz C, Marginet R, Navarro J-T, Ribera J-M, Ariza A. Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. Histopathology. 2011;59:672–8.CrossRefGoogle Scholar
  30. Taylor CR. Hodgkin’s disease is a non-Hodgkin’s lymphoma. Hum Pathol. 2005;36:1–4.CrossRefGoogle Scholar
  31. The National Cancer Action Team and The Royal College of Pathologists. Additional best practice commissioning guidance for developing haematology diagnostic services. (in line with the NICE improving outcomes guidance for haemato-oncology). http://www.rcpath.org/publications-media/publications
  32. The Royal College of Pathologists. Standards for specialist laboratory integration and dataset for the histopathological reporting of lymphomas. 2015. https://www.rcpath.org/uploads/assets/uploaded/dc15eefa-4b49-461d-a292fa44a6541e03.pdf.
  33. The Royal College of Pathologists. Standards and datasets for reporting cancers. Dataset for histopathological reporting of cancer of unknown primary (CUP) or malignancy of unknown primary origin (UO). 2018. www.rcpath.org/uploads/assets/uploaded/d060a31a-b4b5-4e05-8396b65125b7fa87.pdf.
  34. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–15.CrossRefGoogle Scholar
  35. Treon SP, Xu L, Yang G, et al. MYD88L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med. 2012;367:826–33.CrossRefGoogle Scholar
  36. Warnke RA, Weiss LM, Chan JKC, Cleary ML, Dorfman RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology, vol. 3. Washington, DC: AFIP; 1995.Google Scholar
  37. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703–14.  https://doi.org/10.1182/blood-2018-11-881268.CrossRefPubMedPubMedCentralGoogle Scholar
  38. Wilkins BS, Wright DH. Illustrated pathology of the spleen. Cambridge: Cambridge University Press; 2000. p. 1–31.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Institute of PathologyRoyal Victoria HospitalBelfastUK

Personalised recommendations